Diabetics are more likely to develop Alzheimer’s than the general public. Could a popular diabetes and weight-loss drug also stave off dementia?

Now, a new study published in JAMA Network Open suggests that for people with obesity and type 2 diabetes, these drugs—known as GLP-1 receptor agonists —may also reduce the risk of death and lower the ...

FAT jabs are better than widely prescribed metformin when it comes to curbing dementia risk in people with type 2 diabetes, ...

The popular diabetes and weight-loss drug semaglutide may lower the risk of dementia when taken by Type 2 diabetes patients, new research from the Case Western Reserve School of Medicine suggests.

Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.

A new study found that semaglutides like Ozempic are linked to a lower risk of Alzheimer's disease and dementia. Below, a neurologist explains the connection.

THEY’VE been hailed as miracle weight-loss jabs – but the effects of Ozempic-style drugs could go far beyond the waistline. New research suggests these so-called “skinny pens” may also ...

Weight loss drug Ozempic may also reduce the risk of dementia, suggests a new study. American researchers found that semaglutide - the active ingredient in Ozempic and another weight loss ...

A new scientific study has found that weight loss jabs such as Mounjaro and Ozempic can help protect against serious health ...

Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.

Researchers at Case Western Reserve University have discovered that the popular diabetes and weight-loss drug Ozempic may lower a person’s risk of developing dementia.. The active ingredient in ...